CKD-331 clinical trials
Also written CKD-331.
How each study uses CKD-331 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- CKD-331
- 2
Studies by the year they started
3 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses CKD-331 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2)CompletedPhase 1Chong Kun Dang PharmaceuticalNCT06088017Written as CKD-331, D337
- Study to Evaluate the Safety and Pharmacokinetics of CKD-331CompletedPhase 1Chong Kun Dang PharmaceuticalNCT05335044Written as CKD-331
- A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary HypercholesterolemiaStatus unknownPhase 3Chong Kun Dang PharmaceuticalNCT05657574Written as CKD-331